Under the new crown epidemic, the IVD industry has attracted attention. Since the end of 2019, the continuous fermentation of the new crown epidemic has prompted my country's in vitro diagnostic industry to stand on the front line of the fight against the new crown epidemic, and completed the development of diagnostic reagents in a short period of time, acting as an anti-epidemic pioneer in early disease diagnosis. The in vitro diagnostic industry has become one of the biggest highlights of this sudden public health incident. In 2020, the social responsibility, mission, and R&D and innovation capabilities of Chinese IVD companies have been fully reflected. Looking back on the long history of the development and progress of laboratory medicine, the important role of laboratory medicine and in vitro diagnosis in the process of prevention, diagnosis, and disease treatment cannot be replaced by any discipline.

During the COVID-19 pandemic, most companies in the IVD industry performed well. In terms of revenue, the disclosed financial report for the third quarter of 2020 shows that 11 IVD companies have revenue of more than 1 billion yuan in the third quarter of 2020, and 4 IVD companies have revenue of more than 5 billion yuan in the third quarter of 2020. Among them, Mindray Medical led the industry with a revenue of RMB 16.64 billion in the third quarter. In terms of revenue growth, the operating revenue of the four companies in the third quarter more than doubled year-on-year. In 2020, Shengxiang Biotechnology will achieve operating revenue of more than 10 times the level of the same period of the previous year, and the growth rate is faster than that of its peers. In terms of net profit, according to the existing third-quarter financial reports, the net profit of 6 companies in the third quarter reached more than 1 billion, of which Mindray Medical was 5.364 billion, which even exceeded the total revenue of many companies in the third quarter. In terms of net profit growth, the net profit of 6 companies in the third quarter increased by more than 1 times year-on-year, and 3 of them achieved net profit of more than 10 times in the same period last year. Shengxiang Biological has performed well in terms of net profit growth, and its net profit in the third quarter increased by 10702.39% year-on-year. According to the disclosed annual report, it is not uncommon for IVD companies in 2020 to obtain operating income and net profit that are several times higher than that of the same period of the previous year: BGI has stood out with a performance of 8.432 billion yuan, and Daan Gene and Shengxiang Bio The performance of 5.345 billion yuan and 4.767 billion yuan followed closely behind. In terms of revenue growth, Shengxiang Bio and Oriental Biosciences led the growth rates of 1204.67% and 787.92% respectively. The rapid development of Shengxiang Biotechnology was driven by the epidemic and the unique industry advantages of the in vitro diagnostic business in this context.

In the post-epidemic era, there are two major considerations for the IVD industry. This sudden new crown epidemic has caused some IVD companies, especially those related companies whose main business is molecular diagnosis, to usher in explosive growth in the short-term performance. At the same time, we have deeply thought about the entire IVD industry under the new crown epidemic and the companies whose main business is non-molecular diagnostics. Mainly include: aside from the catalysis of the new crown epidemic, the overall development and prospects of the domestic IVD industry itself. For example, the domestic IVD market space and growth rate, the domestic IVD segment market share and domestic substitution process, the impact of domestic centralized procurement policies on the IVD industry, and the development trend of the domestic IVD industry. In addition, we have considered more in-depth the areas of molecular diagnostics with outstanding performance under the new crown epidemic, considered the main technical means, application fields and domestic market of molecular diagnostics, and then considered the entire molecular diagnostics industry in the post-epidemic era.

Based on the above two thoughts on the IVD industry-IVD industry series reports. Based on the above two points of thinking, we set out to write a series of reports on the IVD industry. In this report, we will develop along two different development trends that are characteristic of the in vitro diagnostic industry: one is chemiluminescence that is developing towards a more "high, precise, and integrated" direction;